8
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T7791 |
Iberdomide
CC-220 |
Apoptosis; Ligand for E3 Ligase | Apoptosis; PROTAC |
Iberdomide (CC-220) 是一种口服有效的 cereblon E3 连接酶调节剂,对 cereblon 结合亲和力的 IC50约为150 nM。它是沙利度胺的衍生物,具有抗肿瘤和免疫刺激活性。 | |||
T1979 |
AVN-944
VX-944 |
Dehydrogenase | Metabolism |
AVN-944 (VX-944) 是一种选择性的、非竞争性 IMPDH 抑制剂,对IMPDH1和IMPDH2的Ki=为6-10nM。 | |||
T19661 |
8-Chloroadenosine
NSC 354258,8-Cl-Ado,NSC354258,NSC-354258,8-氯腺嘌呤核苷 |
AMPK | Chromatin/Epigenetic; PI3K/Akt/mTOR signaling |
8-Chloroadenosine (NSC-354258) 是一种 5' AMP 激活的蛋白激酶激动剂,可能用于治疗慢性淋巴细胞白血病。 它的活性与 mTOR 通路的抑制有关。它是一种核苷类似物。在体内代谢为 8-氯-ATP。在转录过程中掺入 RNA 并抑制 RNA 合成。在 MM.1S、RPMI-8226 和 U266 癌细胞系中表现出细胞毒性;在 A549 和 H1299 细胞中诱导 G2/M 细胞周期停滞和有丝分裂灾难。它已被证明可消耗 ATP 并抑制血液恶性肿瘤以及肺癌和乳腺癌细胞系中的肿瘤生长。 | |||
T79523 |
HDAC6-IN-18
|
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
HDAC6-IN-18(化合物4)是首个针对HDAC6亚型的不可逆选择性抑制剂,显示出有效的抗多发性骨髓瘤活性。该抑制剂在RPMI8266、U266以及MM.1S细胞系中表现出对HDAC6的抑制效力,其IC50值分别为0.17、0.7和0.42 μM[1]。 | |||
T70244 | JRN73958 | ||
JRN73958 is an important precursor for the synthesis of scytonemin, also called Reduced scytonemin. Scytonemin is a biological pigment synthesized by many strains of cyanobacteria, including Calothrix sp., Lyngbya aestuarii, and others. Scytonemin is also a potent PKL1 inhibitor, which inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in many cancel cells. Scytonemin was able to inhibit the proliferation of three myeloma cells in a dose-dependent manner, whi... | |||
T71293 |
Nifuroxazide-d4
|
||
Nifuroxazide-d4 is intended for use as an internal standard for the quantification of nifuroxazide by GC- or LC-MS. Nifuroxazide is a nitrofuran antibiotic. It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli. It inhibits quorum sensing and virulence factor production in P. aeruginosa. Nifuroxazide inhibits STAT3 activity in a reporter assay and decreases viability of U266 and INA-6 myeloma cells, which have constitutive S... | |||
T2558 |
Cladribine
2-chlorodeoxyadenosine,克拉屈滨,2-Chloro-2′-deoxyadenosine,CldAdo,2CdA |
Apoptosis; Adenosine deaminase | Apoptosis; Metabolism |
Cladribine (2CdA) 是一种嘌呤核苷类似物,是具有口服活性的腺苷脱氨酶抑制剂。它能作为 DNA 合成的抑制剂,可阻断受损 DNA 的修复。它可抑制 DNA 甲基化,具有抗淋巴瘤活性,可研究血液恶性肿瘤和多发性硬化。 | |||
T70977 |
JMN13497
|
||
JMN13497 is an precursor compound to for synthesis of scytonemin. Scytonemin is a biological pigment synthesized by many strains of cyanobacteria, including Calothrix sp., Lyngbya aestuarii, and others. Scytonemin is also a potent PKL1 inhibitor, which inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in many cancel cells. Scytonemin was able to inhibit the proliferation of three myeloma cells in a dose-dependent manner, while U266 was the most sensitive on... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TCS2170 |
2,5-Dihydroxyacetophenone
Quinacetophenone,2-Acetylhydroquinone,2-5-dihydroxyacetophenone,2 ',5'-二羟基苯乙酮,Acetylhydroquinone,2,5-二羟基苯乙酮,DHAP |
ERK; NF-κB; Tyrosinase | MAPK; NF-κB; Proteases/Proteasome |
2,5-Dihydroxyacetophenone (Quinacetophenone) 是从熟地黄中分离出的一种天然产物,通过阻断 ERK1/2和 NF-κB 信号通路,抑制活化巨噬细胞中炎症介质的产生。 | |||
TN3870 |
Iriflophenone 2-O-Rhamnoside
Dimethylmatairesinol |
Others | Others |
Dimethylmatairesinol can reduce the amount of Immunoglobulin E (IgE) secreted by human myeloma U266 cells, it has potential as an anti-allergic agent. Dimethylmatairesinol also exhibits significant cytotoxicity against three human tumor cells(A-549 lung c | |||
T70495 | Scytonemin | ||
Scytonemin is a biological pigment synthesized by many strains of cyanobacteria, including Calothrix sp., Lyngbya aestuarii, and others. Scytonemin is also a potent PKL1 inhibitor, which inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in many cancel cells. Scytonemin was able to inhibit the proliferation of three myeloma cells in a dose-dependent manner, while U266 was the most sensitive one to scytonemin. Scytonemin , representing a novel Plk1 inhibitor, ... |